A novel druggable DYRK3/CAMKV signaling module for Neuroblastoma tumor growth inhibition.
Rozen, E. J.; Wigglesworth, K.; Shohet, J. M.
Show abstract
High-risk Neuroblastoma is a very aggressive and deadly pediatric cancer, accounting for over 15% of all childhood cancer mortality. Therefore, novel therapeutic strategies for the treatment of neuroblastoma are urgently sought for. Here, we identified the DYRK3 kinase as a critical mediator of neuroblastoma cell proliferation and in vivo tumor growth. Our data suggest a role for DYRK3 as a regulator of the neuroblastoma-specific protein CAMKV, which is also required for neuroblastoma cell proliferation. We show that CAMKV is phosphorylated by DYRK3, and that inhibition of DYRK3 kinase activity induces CAMKV aggregation, probably mediated by its highly disordered C-terminal half. Importantly, we provide evidence that the DYRK3/CAMKV signaling module could play an important role in the regulation of the mitotic spindle during cell division, supporting the idea that inhibition of DYRK3 and/or CAMKV in neuroblastoma cells could constitute an innovative and highly specific intervention to fight against this dreadful pediatric cancer.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- GDAP1 loss of function inhibits the mitochondrial pyruvate dehydrogenase complex by altering the actin cytoskeleton 94%
- In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID 94%
- Indirect CRISPR screening with photoconversion revealed key factors of drug resistance with cell-cell interactions 93%
Similar papers in this journal
- High Tau Expression Correlates with Reduced Invasion and Prolonged Survival in Ewing Sarcoma 94%
- The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma 94%
- Inhibiting BCKDK in triple-negative breast cancer suppress protein translation, impair mitochondrial function, and potentiate doxorubicin cytotoxicity 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.